Article
Cardiac & Cardiovascular Systems
Hanzohra Upur, Jia-Li Li, Xiao-Guang Zou, Yu-Ying Hu, He-Yin Yang, Alimujiang Abudoureyimu, Anwar Abliz, Mamatili Abdukerim, Min Huang
Summary: Objective Admission hyperglycemia is associated with poor prognosis in patients with acute myocardial infarction (AMI), but the effects of baseline diabetes status on this association remain elusive. This retrospective cohort study aimed to investigate the impact of admission hyperglycemia on short and long-term outcomes in diabetic and non-diabetic AMI patients. The study found that admission hyperglycemia predicted worse short and long-term outcomes in AMI patients, with or without diabetes, suggesting the need for further exploration.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Anne M. Kerola, Anne Grete Semb, Markus Juonala, Antti Palomaki, Paivi Rautava, Ville Kyto
Summary: This study found that patients with type 1 diabetes have significantly poorer long-term cardiovascular prognosis after myocardial infarction compared to patients without diabetes, with a higher incidence of major adverse cardiovascular events. The results highlight the importance of effective secondary prevention after myocardial infarction in patients with type 1 diabetes.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Endocrinology & Metabolism
Shiqun Chen, Zhidong Huang, Liling Chen, Xiaoli Zhao, Yu Kang, Wenguang Lai, Xiaozhao Lu, Yang Zhou, Yibo He, Haozhang Huang, Qiang Li, Jin Liu, Yan Liang, Shaohong Dong, Ning Tan, Yong Liu, Jiyan Chen
Summary: Based on the analysis of data from two cohorts in the United States and China, it was found that critical AMI patients with diabetes mellitus have a higher 30-day and 1-year mortality compared to non-diabetic patients. Further studies focusing on prevention and management strategies for diabetes in this specific population are needed.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Medicine, Research & Experimental
T. Schmitz, E. Harmel, M. Heier, A. Peters, J. Linseisen, C. Meisinger
Summary: This study investigated the association between inflammatory markers and 28-day mortality in ST-elevation myocardial infarction patients. Certain biomarkers were found to be significantly associated with mortality, and a combined biomarker score showed improved predictive ability compared to the established GRACE score. These inflammatory markers may play a significant role in the pathophysiology of acute myocardial infarction.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Sheng-Fu Liu, Chih-Kuo Lee, Kuan-Chih Huang, Lian-Yu Lin, Mu-Yang Hsieh, Ting-Tse Lin
Summary: The study found that the use of beta-blockers in rheumatoid arthritis (RA) patients can reduce the all-cause mortality after myocardial infarction (MI). Among them, treatment with non-selective beta-blockers was significantly associated with a lower risk of mortality.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Kongyong Cui, Rui Fu, Jingang Yang, Haiyan Xu, Dong Yin, Weihua Song, Hongjian Wang, Chenggang Zhu, Lei Feng, Zhifang Wang, Qingsheng Wang, Ye Lu, Kefei Dou, Yuejin Yang
Summary: This study assessed the predictive value of stress hyperglycemia ratio (SHR) for long-term mortality after acute myocardial infarction (AMI) in patients with and without diabetes. The results showed a strong positive association between SHR and long-term mortality in both diabetic and nondiabetic patients, suggesting that SHR should be considered a useful marker for risk stratification in these patients.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2022)
Article
Cardiac & Cardiovascular Systems
Timo Schmitz, Eva Harmel, Margit Heier, Annette Peters, Jakob Linseisen, Christa Meisinger
Summary: The study investigated the prevalence of undiagnosed impaired glucose tolerance and type-2-diabetes (T2D) among patients with acute myocardial infarction (AMI) and found that a significant number of patients without known diabetes have elevated HbA1c values. Although no evidence was found for a higher risk of premature mortality in these patients, early detection and appropriate treatment may reduce diabetes-associated complications and improve long-term outcomes.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Elzbieta Paszek, Maciej Polak, Agata Hanna Bryk-Wiazania, Malgorzata Konieczynska, Anetta Undas
Summary: This study found that elevated plasma FXI levels are associated with increased risk of cardiovascular events, including mortality, in patients with type 2 diabetes. These findings suggest that anti-FXI agents may be a potential novel antithrombotic option for this disease.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Endocrinology & Metabolism
T. Schmitz, D. Freuer, E. Harmel, M. Heier, A. Peters, J. Linseisen, C. Meisinger
Summary: This study investigated the association between stress hyperglycemia ratio (SHR) and admission blood glucose with short- and long-term mortality in diabetic and non-diabetic acute myocardial infarction (AMI) patients. The results showed a nonlinear association between higher admission glucose and SHR with higher 28-day mortality in both diabetic and non-diabetic patients. However, the association with long-term mortality was only significant in diabetic patients. These findings suggest that stress hyperglycemia plays a significant role in short-term prognosis for AMI patients, but less so for long-term prognosis.
ACTA DIABETOLOGICA
(2022)
Article
Medicine, General & Internal
Ygal Plakht, Harel Gilutz, Arthur Shiyovich
Summary: This study evaluated the prognostic significance of HbA(1C) levels and changes among diabetic patients after non-fatal AMI. The results showed that fluctuations in HbA(1C) values, especially rapid increases, were associated with a higher risk of mortality. Monitoring both absolute HbA(1C) values and their changes could help predict long-term outcomes in AMI-DM patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Cardiac & Cardiovascular Systems
Youngju Kim, Sungwook Byun, Hee-Yeol Kim, Dong-Bin Kim
Summary: Beta-blockers are commonly used for the treatment of myocardial infarction, but the evidence supporting their effectiveness is based on outdated data. This review found that long-term (≥1 year) use of beta-blockers did not reduce mortality in post-MI patients without clinical heart failure in the reperfusion era. Further research is needed to evaluate the discontinuation of beta-blockers after an acute MI.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Weimin Bai, Benchuan Hao, Lijun Xu, Ji Qin, Weihao Xu, Lijie Qin
Summary: This study showed that the frailty index based on laboratory tests (FI-Lab) is strongly associated with mortality risk in patients with critical acute myocardial infarction (AMI). Adding FI-Lab to existing risk stratification scoring systems improved prediction of in-hospital and 1-year mortality.
FRONTIERS IN MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Maria Fedchenko, Zacharias Mandalenakis, Kok Wai Giang, Annika Rosengren, Peter Eriksson, Mikael Dellborg
Summary: Patients with congenital heart disease have a higher risk of myocardial infarction compared to controls, and also a higher risk of developing new-onset heart failure, recurrent MI, or death after the index MI. Proper management of modifiable cardiovascular risk factors is crucial in reducing morbidity and mortality in these patients.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Linda Vixner, Kristina Hambraeus, Bjorn Ang, Lars Berglund
Summary: This study investigated the impact of pain after myocardial infarction (MI) on mortality. The results showed that pain 1 year after MI increases the risk of all-cause mortality, and this effect is more pronounced than smoking. Clinicians should consider patients' experienced pain when managing patients after MI.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Medicine, General & Internal
Susanne Bendesgaard Pedersen, Jens Cosedis Nielsen, Hans Erik Botker, Aparna Udupi, Jeffrey J. Goldberger
Summary: This study aimed to investigate the association between beta-blocker dose and mortality following acute myocardial infarction. A nationwide cohort study in Denmark was conducted, and the results showed that any dose of beta-blocker was associated with a significant reduction in mortality compared to no treatment. The largest reduction in mortality was observed within the first year after acute myocardial infarction for doses >25%-50% of the recommended target dose, suggesting that higher doses are unnecessary.
AMERICAN JOURNAL OF MEDICINE
(2023)